Work

A phase 1, first-in-human study of DS5361, a small-molecule, nonsense-mediated mRNA decay (NMD) inhibitor in patients with advanced/metastatic solid tumors (parts 1 and 2).

Year: 2026

Type: article

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.tps2680

Authors: Shiraj Sen, Benedito A. Carneiro, Judy S. Wang, Shigehiro Koganemaru, Shigehisa Kitano, Naoto Yoshizuka, Shota Mizuno, Abdul Waheed Rajper, Ang Li, Anthony W. Tolcher

Institutions: Brown University, National Cancer Center Hospital East, The Cancer Institute Hospital, Japanese Foundation For Cancer Research, Daiichi Sankyo (United States), Daiichi-Sankyo (Japan)

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Daiichi Sankyo Europe

OpenAlex ID: W7162684809

FWCI:

Cites:

Cited by:

Related to: